This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Singulair

Merck & Co., Inc.

Drug Names(s): montelukast sodium, Kipres, MK0476

Description: Singulair (Montelukast) is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.

The cysteinyl leukotrienes are products of arachidonic acid metabolism and are released from various cells including eosinophils and mast cells. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found on human airway and proinflammatory cells and its activation correlates with asthma and allergic rhinitis.

Partners: Kyorin Pharmaceutical Co., Ltd.


Singulair News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug